marpai health is working at the intersection of healthcare and deep learning, the most advanced form of artificial intelligence. our mission is to predict and prevent costly events in healthcare for the benefit of patients, providers and payors.
Company profile
Ticker
MRAI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Marpai Captive, Inc. • Marpai Administrators, LLC • Marpai Health, Inc. • EYME Technologies, Ltd. • Maestro Health, LLC ...
MRAI stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
17 Apr 24
DEFR14A
Revised proxy
17 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
MARPAI reports FOURTH QUARTER AND FULL YEAR 2023 financial results
26 Mar 24
PRE 14A
Preliminary proxy
18 Mar 24
DEF 14A
Definitive proxy
14 Mar 24
8-K
Other Events
13 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Mar 24
8-K/A
Marpai Announces Preliminary Unaudited Financial Results for Fourth Quarter and Full Year 2023
6 Mar 24
8-K
Marpai Announces Preliminary Unaudited Financial Results for Fourth Quarter and Full Year 2023
6 Mar 24
Transcripts
MRAI
Earnings call transcript
2023 Q4
27 Mar 24
MRAI
Earnings call transcript
2023 Q2
3 Aug 23
MRAI
Earnings call transcript
2023 Q1
11 May 23
MRAI
Earnings call transcript
2022 Q4
30 Mar 23
MRAI
Earnings call transcript
2022 Q3
13 Nov 22
MRAI
Earnings call transcript
2022 Q2
13 Aug 22
MRAI
Earnings call transcript
2022 Q1
15 May 22
MRAI
Earnings call transcript
2021 Q4
31 Mar 22
Latest ownership filings
SC 13D/A
Lamendola Damien
11 Mar 24
4
Damien Lamendola
8 Mar 24
SC 13G/A
Altium Capital Management LP
13 Feb 24
SC 13D/A
EITAN YARON
19 Jan 24
SC 13D/A
Lamendola Damien
19 Jan 24
4
John Paul Powers
18 Jan 24
3
John Paul Powers
18 Jan 24
4
Damien Lamendola
17 Jan 24
4
Jennifer Rosario Calabrese
17 Jan 24
4
ROBERT M PONS
17 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.25 mm | 14.25 mm | 14.25 mm | 14.25 mm | 14.25 mm | 14.25 mm |
Cash burn (monthly) | 2.19 mm | (no burn) | 2.43 mm | 2.73 mm | 2.20 mm | 2.94 mm |
Cash used (since last report) | 15.03 mm | n/a | 16.67 mm | 18.73 mm | 15.05 mm | 20.12 mm |
Cash remaining | -776.34 k | n/a | -2.42 mm | -4.48 mm | -797.16 k | -5.87 mm |
Runway (months of cash) | -0.4 | n/a | -1.0 | -1.6 | -0.4 | -2.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 2 |
Closed positions | 6 |
Increased positions | 2 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 232.96 mm |
Total shares | 16.79 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Damien Lamendola | 8.62 mm | $10.52 mm |
Edmundo Gonzalez | 7.83 mm | $0.00 |
Sabby Management | 299.08 k | $197.69 mm |
Geode Capital Management | 33.13 k | $22.75 mm |
HRT Financial | 10.93 k | $7.00 k |
Tower Research Capital | 2.91 k | $1.92 mm |
BLK Blackrock | 82.00 | $54.00 k |
WFC Wells Fargo & Co. | 35.00 | $23.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Mar 24 | Damien Lamendola | Class A Common Stock | Buy | Acquire P | Yes | No | 1.65 | 910,000 | 1.50 mm | 2,861,306 |
17 Jan 24 | Jennifer Rosario Calabrese | Class A Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 50,000 |
17 Jan 24 | Michael Charles Dendy | Class A Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 103,850 |
16 Jan 24 | Damien Lamendola | Class A Common Stock | Buy | Acquire P | Yes | No | 0.9201 | 1,100,000 | 1.01 mm | 1,951,306 |
16 Jan 24 | Yaron Eitan | Class A Common Stock | Buy | Acquire P | No | No | 0.9201 | 210,000 | 193.22 k | 601,454 |
Press releases
MARPAI INC. BOLSTERS SALES TEAM WITH TWO WORLD-CLASS EXECUTIVES
24 Apr 24
MARPAI INC. ANNOUNCES SALE OF $11.83 MILLION CONVERTIBLE NOTES
16 Apr 24
MARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
26 Mar 24
NASDAQ PANEL GRANTS MARPAI'S REQUEST FOR EXTENSION TO COMPLY WITH CONTINUED LISTING REQUIREMENTS
13 Mar 24
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?
11 Mar 24